Re: 3 Weeks To The 31st

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: 3 Weeks To The 31st

in response to

3 Weeks To The 31st

SanFrancisco99

posted on Mar 10, 2017 11:22AM

SanFran,

I agree that it would be great if we received some new information in conjunction with this abstract about the clinical efficacy of ZEN-3694.

Keep in mind that although the abstract embargo is lifted on Friday March 31, Zenith doesn't present their poster until Monday April 3. The poster/presentation may contain updated or additional information that was not included in the abstract, which had to be submitted in January. A lot can change in a couple of months!

So I would wait until Monday April 3 to make a judgement, just in case a news release tags along with the April 3 presentation.